Breaking The Bottleneck: How Modular Workflows Are Redefining CAR T Manufacturing Performance, Flexibility, And Scalability

As CAR T therapies move closer to commercial-scale production, manufacturing strategies must support both reliable cell quality and operational agility. Flexible modular workflows offer a way to adapt processes as requirements evolve, while maintaining control over key quality attributes such as transduction efficiency, T cell activation, expansion, and phenotype preservation. Comparative data show that modular Gibco™ CTS™ workflows can deliver strong performance, including transduction efficiency approaching 80% by day 8, increased CAR+ T cell yields, and enrichment of stem cell-like memory T cell populations associated with therapeutic potential. These workflows can also support parallel processing, reduce instrument lock times, and improve throughput without sacrificing purity or isolation efficiency.

Learn how modular approaches can help future-proof cell therapy manufacturing from early development through commercial production.